The over-representation of PIK3CA in Saudi CRC samples in this study was associated with increased levels of ABCC1 transporter and mutated KRAS, all of which could be important determinants for choosing suitable drug combinations for Saudi CRC patients. Here, KRAS is linked to colorectal carcinoma.